United Therapeutics Corporation
UTHR
Jodie situation report
United Therapeutics Corporation's current read is isolated; its market group is not confirming.
The latest filing evidence is available. 0 of 37 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 10 directly disclosed connections are confirming.
- Revenue decreased 1.9% versus the comparable filing period.
- R&D expense rose 9.2%, with United Therapeutics citing higher expenditures on cardiopulmonary treatment projects and acquisition-related obligations.
- R&D expense declined year-over-year driven primarily by lower milestone payments for drug delivery device technologies; monitor milestone payment trends and R&D spend changes.
Invalidation: The isolated read changes if UTHR's group or a disclosed connection begins moving with it.
Who this business touches
The relationships behind UTHR
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
Depended on by
LQDALiquidia CorporationcompetitorMay 11, 2026 ▾
“Our Treprostinil Injection product to treat PAH faces competition primarily from the continued use of the branded Remodulin sold by United Therapeutics as well as additional generic treprostinil products offered by Teva, Par Pharmaceutical, Dr.”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 7 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
UTHR is currently a Follower in the organic co-movement group Biotechnology. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.